Navigation Links
Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
Date:9/19/2007

Application Would Expand Versatility of DelSite cGMP Polymer

IRVING, Texas, Sept. 19 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Pink Sheets: CARN) today announced its wholly-owned subsidiary, DelSite Biotechnologies, Inc., entered into a technology evaluation rights license agreement with a biotechnology company for transdermal delivery of vaccines using GelSite(R) polymer, DelSite's high-molecular-weight anionic polysaccharide which is produced under cGMP with high purity at a kilogram scale. Financial terms of the agreement were not disclosed.

As part of the agreement, DelSite will provide GelSite(R) polymer and assistance in formulation development of a transdermal vaccine. Transdermal vaccination avoids needle sticks, pain or tissue damage and offers distinct advantages over conventional vaccination regimens. The objective of the program is to develop an effective vaccine formulation that may further enhance the immune response following through-the-skin delivery. The GelSite(R) polymer's distinct chemical and functional properties, including its capability for in-situ gel formation that provides a matrix for sustained antigen release, may make it an especially suitable platform for noninvasive transdermal vaccination delivery.

This agreement is a new addition to DelSite's delivery technology programs in the vaccine areas. So far this year, DelSite has entered into five technology rights evaluation agreements with commercial partners in using GelSite(R) polymer for drug or vaccine delivery by various routes. These include intranasal delivery of a Shigellosis vaccine by EndoBiologics, Inc.; intranasal delivery of peptide/protein therapeutics by Nastech Pharmaceutical Company, Inc.; injectable delivery of an HIV peptide vaccine by AriaVax, Inc.; injectable delivery of a cancer therapeutic agent by ElSohly Laboratories; and sublingual delivery of vaccines by the International Vaccine Institute.

Additionally, DelSite initiated work with the National Institutes of Health to evaluate a modification of its GelSite(R) polymer for use as the antigen for a typhoid vaccine, and with the National Cancer Institute for development of needle-free nasal powder delivery of future HPV vaccines.

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institutes of Health) under the Department of Health and Human Services.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. More than 130 patents in 26 countries protect Carrington's technology. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge subsidiary to provide software to Mayo clinic
2. Merge subsidiary gets assets of Paris medical software firm
3. Renaissance Learning sells unprofitable subsidiary
4. WARF enters licensing agreements for stem cell products
5. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
6. Software company enters health space with RFID solutions on hold
7. Lucigen Corp. enters global licensing agreement
8. Call centers and customer service: The good, the bad, and the clueless
9. GE Healthcare enters agreement with Canadian health authority
10. Data centers: Buyers beware of over-hyped facilities
11. Data centers: Blowing smoke and raising red flags
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... May 19, 2017 , ... The ... Academic researchers with technologies ripe for commercialization, and who are affiliated with the ... encouraged to submit proposals. QED, now in its tenth round, is the first ...
(Date:5/18/2017)... VIRGINIA (PRWEB) , ... May 17, 2017 , ... NDA ... business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development ... addition to his position at Eurofins and Cardinal Health, he was former Chief Operating ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... equipment for varying industries, including food and dairy, munitions, and pharmaceutical/biotech, recently introduced ... safety and ease of use. The improvement in technology comes on the heels ...
(Date:5/16/2017)... , ... May 16, 2017 , ... ... announced its global Genedata Screener User Group Meetings, which will be ... the opportunity to share best practices in screening data analysis and learn about ...
Breaking Biology Technology:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
Breaking Biology News(10 mins):